Filtered By:
Condition: Thrombosis
Cancer: Leukemia
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Cancers, Vol. 15, Pages 3060: Arterial Thrombosis in Patients with Acute Myeloid Leukemia: Incidence and Risk Factors
Conclusions: Our study showed that patients with AML are at increased risk of ATE. The risk was increased in patients with cardiovascular comorbidities, previous thrombosis, adverse cytogenetic risk as well as BMI > 30.
Source: Cancers - June 5, 2023 Category: Cancer & Oncology Authors: Mirjana Mitrovic Nikola Pantic Nikica Sabljic Zoran Bukumiric Marijana Virijevic Zlatko Pravdic Mirjana Cvetkovic Jovan Rajic Jelena Bodrozic Violeta Milosevic Milena Todorovic-Balint Ana Vidovic Nada Suvajdzic-Vukovic Darko Antic Tags: Article Source Type: research
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease
CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.PMID:36951061 | DOI:10.1161/ATVBAHA.122.318928
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 23, 2023 Category: Cardiology Authors: Nadia Akhiyat Terra L Lasho Morsaleh Ganji Takumi Toya Chang-Xin Shi Xianfeng Chen Esteban Braggio Ali Ahmad Michel T Corban Keith Stewart Jenna Fernandez Zhuoer Xie Christy Finke Lilach O Lerman Mrinal M Patnaik Amir Lerman Source Type: research
Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan
CONCLUSIONS: ET and pre-PMF-T were two distinct disease entities and exhibited different clinical phenotype, genotype, and outcomes.PMID:36857745 | DOI:10.1093/ajcp/aqac173
Source: American Journal of Clinical Pathology - March 1, 2023 Category: Pathology Authors: Ming-Chung Kuo Wen-Yu Chuang Hung Chang Tung-Huei Lin Jin-Hou Wu Tung-Liang Lin Che-Wei Ou Yu-Shin Hung Ting-Yu Huang Ying-Jung Huang Po-Nan Wang Lee-Yung Shih Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Transfusion thresholds for guiding red blood cell transfusion
CONCLUSIONS: Transfusion at a restrictive haemoglobin concentration decreased the proportion of people exposed to RBC transfusion by 41% across a broad range of clinical contexts. Across all trials, no evidence suggests that a restrictive transfusion strategy impacted 30-day mortality, mortality at other time points, or morbidity (i.e. cardiac events, myocardial infarction, stroke, pneumonia, thromboembolism, infection) compared with a liberal transfusion strategy. Despite including 17 more randomised trials (and 8846 participants), data remain insufficient to inform the safety of transfusion policies in important and sele...
Source: Cochrane Database of Systematic Reviews - December 21, 2021 Category: General Medicine Authors: Jeffrey L Carson Simon J Stanworth Jane A Dennis Marialena Trivella Nareg Roubinian Dean A Fergusson Darrell Triulzi Carolyn Dor ée Paul C H ébert Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cancers, Vol. 12, Pages 1285: Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children
Conclusion: This represents the largest GWAS meta-analysis conducted to date associating SNPs to VTE in children and adolescents treated on childhood ALL protocols. Validation of these findings is needed and may then lead to patient stratification for VTE preventive interventions. As VTE hemostasis involves multiple pathways, a more powerful GWAS is needed to detect combination of variants associated with VTE.
Source: Cancers - May 18, 2020 Category: Cancer & Oncology Authors: Marion K. Mateos Morten Tulstrup Michael CJ Quinn Ruta Tuckuviene Glenn M. Marshall Ramneek Gupta Chelsea Mayoh Benjamin O. Wolthers Pasquale M. Barbaro Ellen Ruud Rosemary Sutton Pasi Huttunen Tamas Revesz Sonata S. Trakymiene Draga Barbaric Ulf Tedg år Tags: Article Source Type: research
